<DOC>
	<DOCNO>NCT00776204</DOCNO>
	<brief_summary>The objective study evaluate completeness strut coverage vessel wall response new generation JACTAX drug-eluting stent v Taxus stent de novo coronary artery lesion 6 month post index procedure . To investigate completeness coverage well number uncovered stent strut per section , high resolution ( ~ 10-15 µm axial ) intracoronary Optical Coherence Tomography ( OCT ) use .</brief_summary>
	<brief_title>The Optical Coherence Tomography Drug Eluting Stent Investigation</brief_title>
	<detailed_description>The risk late stent thrombosis represent major concern patient treat first generation drug-eluting stent ( DES ) . Delayed heal poor endothelialization common finding vessel treat DES probably relate amount drug polymer apply DES . There evidence suggest polymer application may influence process inflammation vessel heal . The JACTAX family DES design provide maximum amount drug deliver directly coronary vessel tissue exclude polymer drug contact within vessel lumen . The JACTAX stent comprise currently market bare metal stent ( Libertè™ ) coat exclusively ablumenal stent surface carrier contain bioerodable polymer , Polylactide paclitaxel . The objective prospective study measure completeness strut coverage vessel wall response ( strut malapposition , neointima disomogeneities texture ) JACTAX stent vs Taxus Libertè de novo coronary artery lesion 6 month post index procedure . Optical Coherence Tomography ( OCT ) detect small degree stent strut coverage accurately IVUS use 6 month follow-up . Intravascular ultrasound ( IVUS ) perform per normal practice index procedures 6 month follow-up .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>General Inclusion Criteria 1 . Patient ≥ 18 year age 2 . Patient eligible percutaneous coronary intervention ( PCI ) 3 . Patient demonstrate leave ventricular ejection fraction ( LVEF ) ≥ 25 % 4 . Patient legal guardian understands agree comply specify study requirement provide write Informed Consent effect . Angiographic Inclusion Criteria 1 . Target lesion de novo native coronary artery lesion ( i.e. , coronary lesion previously treat ) ≤ 25 mm treat single JACTAX , JACTAX LD TAXUS stent 2 . A second lesion second vessel may treat one ( 1 ) TAXUS™ Libertè™ DES bare metal stent . General Exclusion Criteria 1 . The patient life expectancy le 24 month due another medical condition 2 . Patient history hypersensitivity paclitaxel structurally relate compound 3 . Patient exhibit cardiogenic shock ( systolic pressure &lt; 80mm Hg PCWP &gt; 20mm Hg cardiac index &lt; 1.8 liters/minute/m2 intraaortic balloon pump intravenous inotropes need maintain systolic pressure &gt; 80 mm Hg ) time within 24 hour prior index procedure 4 . Patient demonstrate evidence acute chronic renal dysfunction ( serum creatinine &gt; 2.0 mg/dl or177 µmol/l ) 5 . Planned cardiac surgery procedure ≤ 6 month postindex procedure 6 . Patient demonstrate evidence acute myocardial infarction ( eg . STEMI enzyme elevation CK &gt; 2X local laboratory 's ULN unless CKMB &lt; 2X ULN ) 7 ) Cerebrovascular accident ( CVA ) include stroke TIA within previous 3 month 7 . Patient demonstrate evidence leukopenia ( leukocyte count &lt; 3.5 X 109/liter ) 8 . Patient demonstrate evidence thrombocytopenia ( platelet count &lt; 100,000/mm3 ) thrombocytosis ( &gt; 750,000/mm3 ) 9 . Patient contraindicate ASA ( successful prior desensitization ASA exclusion ) , clopidogrel , ticlopidine 10 . Patient currently warfarin , possibility treatment warfarin follow 6 month post index procedure 11 . Patient treat paclitaxel chemotherapeutic agent within 12months prior plan index procedure 12 . Anticipated treatment paclitaxel oral rapamycin period 6months index procedure 13 . Patient receive drug elute stent within 12months prior plan index procedure 14 . Previous plan treatment intravascular brachytherapy target vessel 15 . Known allergy stainless steel 16 . Female male know intention procreate within 3 month index procedure ( due exposure paclitaxel unknown affect may fetus ) 17 . Female childbearing potential positive pregnancy test within 7 day index procedure , lactating , intend become pregnant 9 month post index procedure 18 . Patient opinion investigator clinically appropriate OCT evaluation . Angiographic Exclusion Criteria 1 . Evidence thrombus study vessel , base angiography IVUS 2 . Study lesion totally occlude ( TIMI flow ≤ 1 ) either baseline predilatation 3 . Study lesion , study vessel proximal study lesion moderately severely calcified , visual estimate 4 . Study lesion ostial location ( within 3.0 mm vessel origin ) 5 . Study lesion involve arterial segment highly tortuous anatomy lesion locate within distal &gt; 60 degree bend vessel 6 . Study lesion involve bifurcation diseased ( &gt; 50 % stenotic ) branch vessel &gt; 2.0 mm diameter 7 . Left main coronary artery disease ( stenosis &gt; 50 % ) whether protect unprotected 8 . Target lesion length &gt; 25 mm , base visual estimate operator 9 . Target vessel diameter &gt; 3.5 mm , base visual estimate operator 10 . Target vessel diameter &lt; 2.75 mm base visual estimate operator 11 . Pretreatment target lesion ( exclude predilation ) another interventional device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Percutaneous Coronary Interventions</keyword>
	<keyword>Optical Coherence Tomography</keyword>
</DOC>